Amgen plans to acquire a fellow Californian biotechnology company, ChemoCentryx, for $3.7 billion in a deal meant to deepen its pool of medicines targeting inflammation and the kidneys.
The companies expect their deal, announced Thursday, to close sometime between October and December. Its completion would hand Amgen a few experimental medicines in the early stages of human testing, plus a marketed therapy known as Tavneos, which the Food and Drug Administration approved late last year as a supplemental treatment for a group of rare autoimmune diseases.
